Mustang Bio (MBIO) vs XORTX Therapeutics (XRTX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Mustang Bio is the larger company by market cap ($3.2 million vs $2.6 million), about 1.2 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | MBIO | XRTX |
|---|---|---|
| Share price | $0.4202 | $1.43 |
| Market cap | $3.18M | $2.59M |
| 1-day change | +2.40% | -22.97% |
| Forward P/E | — | 1.78 |
| EPS (TTM) | $-0.44 | $-2.61 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $1.81 | $7.05 |
| 52-week low | $0.3802 | $1.36 |
| Distance from 52-week high | -76.78% | -79.79% |
| Average volume | 29.38K | 376.30K |
| Shares outstanding | 6.73M | 1.82M |
| Employees | 4 | — |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Mustang Bio
MBIO stock →Mustang Bio, Inc., a clinical-stage biopharmaceutical company, focuses on translating cell therapies into cures for difficult-to-treat cancers and autoimmune diseases in the United States. The company develops MB-106, a CD20-targeted chimeric antigen receptor (CAR) T cell therapy which is in Phase I clinical trail for non-hodgkin lymphoma, chronic lymphocytic leukemia, and autoimmune diseases; MB-109, a combination MB-101 and MB-108 as a potential treatment for IL13Ra2+ relapsed or refractory glioblastoma and high-grade astrocytoma; MB-101, an IL13Ra2 CAR T cell program completd Phase I for glioblastoma; and MB-108 which is in Phase I for the treatment of herpes simplex virus-1 oncolytic virus C134.
Health Care · Biotechnology: Pharmaceutical Preparations · 4 employees
About XORTX Therapeutics
XRTX stock →XORTX Therapeutics Inc., a late-stage clinical pharmaceutical company, engages in the development and commercialization of therapies to treat hyperuricemia related diseases in Canada. It develops XRx-026, which is in Phase III for the treatment of gout; XRx-008, which is in Phase II for the treatment of autosomal dominant polycystic kidney disease; XRx-101, which is in Phase II for the treatment of acute kidney injury associated with respiratory virus infection, including sepsis and coronavirus; and XRX-225, which is in preclinical stage for the treatment of type 2 diabetic nephropathy, as well as VB4-P5, a program for the treatment and prevention of fibrosis in the kidney.
Health Care · Biotechnology: Pharmaceutical Preparations
MBIO vs XRTX FAQ
Which is bigger, Mustang Bio or XORTX Therapeutics?
Mustang Bio (MBIO) is larger, with a market capitalization of $3.18M compared with $2.59M for XORTX Therapeutics (XRTX).
Are Mustang Bio and XORTX Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.